Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.72 USD | +0.66% | -5.21% | +12.14% |
Business Summary
Number of employees: 171
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gene Therapeutic Products
100.0
%
| 3 | 100.0 % | 21 | 100.0 % | +562.29% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
97.3
%
| 0 | 1.1 % | 20 | 97.3 % | +57,488.57% |
Netherlands
2.7
%
| 3 | 98.9 % | 1 | 2.7 % | -81.67% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
Fariborz Kamal
PSD | President | 61 | 18-09-30 |
Robert Kim
CTO | Chief Tech/Sci/R&D Officer | 63 | 22-09-30 |
Chief Tech/Sci/R&D Officer | 62 | 22-09-22 | |
Julian Pei
IRC | Investor Relations Contact | - | - |
Scott Bizily
HRO | Human Resources Officer | 52 | 21-08-31 |
An Song
PRN | Corporate Officer/Principal | - | 21-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Jacob Chacko
BRD | Director/Board Member | 45 | 19-02-28 |
Shawn Tomasello
BRD | Director/Board Member | 65 | 20-11-17 |
Director/Board Member | 65 | 20-11-17 | |
Chief Tech/Sci/R&D Officer | 62 | 22-09-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 51,703,412 | 49,347,153 ( 95.44 %) | 0 | 95.44 % |
Company contact information
4D Molecular Therapeutics, Inc.
5858 Horton Street Suite 455
94608, Emeryville
+
http://www.4dmoleculartherapeutics.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.14% | 1.17B | |
+51.85% | 57.87B | |
+41.19% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- FDMT Stock
- Company 4D Molecular Therapeutics, Inc.